Antisense oligonucleotides (ASOs) — short nucleic acid molecules used to modulate protein production — can be used to correct abnormal dopa decarboxylase (DDC) processing in cells from patients with aromatic L-amino acid decarboxylase (AADC) deficiency, a new study reports. The study, “Antisense oligonucleotides modulate dopa decarboxylase function in…
News
PTC Therapeutics plans to request approval for its GT-AADC gene therapy, developed for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency, in the United States. Supported by positive data from clinical studies, the company expects to submit a biologics license application (BLA) with the U.S. Food and Drug Administration…
Recent Posts
- AI model popEVE predicts likelihood of harm from ultra-rare DNA mutations
- Our holiday trip is a symbol of our daughter’s journey after gene therapy
- NORD adds 7 sites in 5 states as Rare Disease Centers of Excellence
- Simple strategies and new exercises help to correct mouth breathing
- New AI tool for doctors’ notes may save patients years to be diagnosed